Related references
Note: Only part of the references are listed.Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
Vera Petrova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma
Rebekka Weber et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Lorenzo Galluzzi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Christopher Groth et al.
BRITISH JOURNAL OF CANCER (2019)
Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma
M. Amini-Adle et al.
BMC CANCER (2018)
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Myeloid-derived suppressor cells coming of age
Filippo Veglia et al.
NATURE IMMUNOLOGY (2018)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
Myeloid-derived suppressor cells and tumor escape from immune surveillance
Viktor Umansky et al.
SEMINARS IN IMMUNOPATHOLOGY (2017)
Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017
Selma Ugurel et al.
EUROPEAN JOURNAL OF CANCER (2017)
IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model
Shuku-ei Ito et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy
Michal Baniyash
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Clinical Significance of Circulating CD33+ CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab
Moshe Sade-Feldman et al.
CLINICAL CANCER RESEARCH (2016)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Vinit Kumar et al.
TRENDS IN IMMUNOLOGY (2016)
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Vincenzo Bronte et al.
NATURE COMMUNICATIONS (2016)
New therapeutic options for advanced non-resectable malignant melanoma
Simone Stadler et al.
ADVANCES IN MEDICAL SCIENCES (2015)
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Christoffer Gebhardt et al.
CLINICAL CANCER RESEARCH (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Paving the road to tumor development and spreading: myeloid-derived suppressor cells are ruling the fate
Yaron Meirow et al.
FRONTIERS IN IMMUNOLOGY (2015)
Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients
Huanhuan Jiang et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy
Joshua P. Landreneau et al.
CANCER MICROENVIRONMENT (2015)
Myeloid-derived suppressor cell heterogeneity in human cancers
Samantha Solito et al.
YEAR IN IMMUNOLOGY: MYELOID CELLS AND INFLAMMATION (2014)
Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy
Yago Pico de Coana et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1-or Melan-A-Specific T Cells
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Cutaneous melanoma
Alexander M. M. Eggermont et al.
LANCET (2014)
Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients
Kimberly R. Jordan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model
Alexandra Sevko et al.
JOURNAL OF IMMUNOLOGY (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
Paola Filipazzi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
On the armament and appearances of human myeloid-derived suppressor cells
Isabel Poschke et al.
CLINICAL IMMUNOLOGY (2012)
Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner
Tillmann Michels et al.
JOURNAL OF IMMUNOTOXICOLOGY (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Restoration of Antitumor Immunity Through Selective Inhibition of Myeloid Derived Suppressor Cells by Anticancer Therapies
L. Apetoh et al.
CURRENT MOLECULAR MEDICINE (2011)
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model
Christiane Meyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism
Galina V. Shurin et al.
JOURNAL OF IMMUNOLOGY (2009)
Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations
Ramon Kaneno et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth
Zhong Hua et al.
CLINICAL CANCER RESEARCH (2007)
Share Paper
